Citations

Clear

4610 citation(s) found for "Lu, Brian".

Abstract 245: Super‐Large‐Bore vs Large‐Bore Aspiration Catheters in Mechanical Thrombectomy: A Multicenter Propensity‐Matched Analysis
Chacon, Alexander , Inoa, Violiza , Cawley, M. F., Rai, Ansaar , Maier, Ilko , Dye, J. A., Ezzeldin, M., Matouk, Charles, Brinjikji, Waleed , Jabbour, Pascal , Almallouhi, E., Dağlıoğlu, Ergün , Spiotta, Alejandro M , Grossberg, Jonathan A , Chacon, A., Alawieh, Ali , Motiwala, Mustafa , Arthur, Adam Stephen , Cawley, M., Howard, Brian M , Siddiqui, F., Alaraj, Ali , Romano, Daniele Giuseppe , Fiorella, David , Dye, J., Wolfe, Stacey Q , Mascitelli, Justin R , Fragata, Isabel , Limaye, Kaustubh , Ogilvy, Christopher S. , Jabbour, Pascal , Almallouhi, Eyad , Park, M. S., Navía, Pedro , Grandhi, Ramesh , Altschul, David , Schirmer, Clemens M. , Paul, Alexandra R , Mokin, Maxim , Goyal, Nitin

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_245 Get It

Background Contact aspiration remains a frontline approach for mechanical thrombectomy (MT) in acute ischemic stroke (AIS). Early evidence correlates catheter size with procedural efficiency and clinical outcomes. Larger‐bore (LB) aspiration catheters may enhance clot ingestion, increase aspiration force, and facilitate faster and more complete recanalization. However, the transition from standard LB catheters (0.068‐0.072″) to super‐large‐bore (SLB, ≥0.080″) devices has raised questions regarding both safety and clinical benefit. Although the use of SLB catheters is increasing, comparative data on their performance versus LB catheters remain limited. This study aims to evaluate the safety and efficacy of SLB compared with LB catheters including data from a large multicenter international registry. Methods We retrospectively analyzed patients with AIS due to LVO treated at 46 international stroke centers between January 2013 and June 2025. Among eligible patients, propensity score matching (PSM) at a 5:1 ratio was used to balance baseline characteristics between those treated with standard LB catheters and those treated with SLB catheters. Safety endpoints included intraprocedural complications, symptomatic intracranial hemorrhage (sICH), distal embolization, and 90‐day mortality. Efficacy endpoints included functional independence at 90 days (modified Rankin Scale [mRS] 0‐2), successful recanalization (TICI ≥2b), first‐pass effect (TICI ≥2b on the first aspiration attempt), and procedural timing to TICI2b. Results A total of 3,100 patients were included (LB n=3,024; SLB n=67). After PSM (LB n=335; SLB n=67), safety outcomes were comparable between groups in terms of intraprocedural complications occurred (p=0.5), sICH (p>0.9), embolization to new territory (p=0.2), and 90‐day mortality (p>0.9). Efficacy outcomes were similarly consistent for functional independence (mRS 0‐2) (p>0.9), successful recanalization (p>0.9), first‐pass effect (p=0.5), and time to TICI ≥2b (27.6 vs. 24.5 minutes; p=0.9). These findings remained consistent in the subgroup with ICA and M1 occlusions, with no significant differences in safety (intraprocedural complications [p=0.4], sICH [p>0.9], embolization to new territory [p=0.6], or 90‐day mortality [p>0.9], nor in efficacy outcomes (functional independence at 90 days [p>0.9], successful recanalization [p=0.9], first‐pass effect [p=0.6], and time to TICI ≥2b [p=0.9]). Conclusion In this large multicenter analysis, the use of SLB aspiration catheters demonstrated comparable safety and efficacy to standard LB catheters for MT in AIS. Despite theoretical advantages in aspiration dynamics, SLB devices did not confer significant procedural or clinical benefit over LB catheters. These findings suggest that while SLB catheters are a feasible alternative, technical and clinical outcomes remain comparable to LB catheters. Further prospective studies are warranted to clarify potential clinical advantages. image
Optimizing procedures for ocular radiation injury studies in the tree shrew
Dalvin, Lauren A. , Anderson, Kjersten J. , Rinkoski, Tommy A. , Miley, David R. , Ong, Hien Thi My , Schechinger, Angela M., Fjeld, Cassandra A., Leblond, Catherine R. , Keown, Mackenzie K. , Palmer, Sierra D. , Carlson, Brett L. , Ott, Lauren L. , Romero, Michael F. , Boynton, Felicia D. Duke , Roddy, Gavin W. , Ong, Hien , Burgenske, Danielle M , Carlson, Brett L , Ott, Lauren L , Samuels, Brian C , Romero, Michael F , Sarkaria, Jann N , Boynton, Felicia Duke , Roddy, Gavin W , Dalvin, Lauren A , Burgenske, Danielle M. , Sarkaria, Jann N.

Mayo Clinic

Exploration of Targeted Anti-tumor Therapy | December 2, 2025 | Volume: 6 | Issue: No issue available | Pages: No page available

10.37349/etat.2025.1002352 | PMID 41357135 Get It

Radiation exposure to the eye during cancer treatment can lead to ocular radiation injury (ORI), a devastating condition that can have a profound and permanent impact on vision-related quality of life. Rodent models do not have adequate ocular anatomy to accurately simulate human ORI, and modeling in non-human primates is limited by logistical and ethical concerns. To improve future translational research investigating ways to treat or prevent ORI, we developed protocols for a tree shrew model of ORI. Northern tree shrews (Tupaia belangeri) were obtained by our laboratory. Custom housing and handling methods were developed, including custom body suits to maintain the tree shrew’s body temperature during procedures. Radiation delivery was optimized to accurately deliver radiation, and imaging was performed to observe fundus changes from ORI. Optimization of tree shrew handling, housing, anesthesia approaches, radiation delivery, and clinically-relevant ocular imaging permitted successful induction and assessment of ORI in tree shrews. With these protocols, tree shrews can be used as a highly relevant model organism with key anatomic features similar to humans to study ORI.
Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta‐Analysis
Brown, Caitlin S. , Engstrom, Kellyn , Faine, Brett , Mattson, Alicia E , Cole, Kristin, Acquisto, Nicole M. , Wieruszewski, Erin D. , Mercer, Kevin , Gerberi, Dana , Brown, Caitlin S , Faine, Brett A , Mattson, Alicia, Acquisto, Nicole M , Wieruszewski, Erin , Mercer, Kevin , Rech, Megan A , Gilbert, Brian W. , Cole, Kristin, Bellolio, Fernanda , Rabinstein, Alejandro A. , Rech, Megan A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | November 28, 2025 | Volume: 9 | Issue: 2 | Pages: No page available

10.1002/jac5.70156 | PMID 42009489 Get It

ABSTRACT Background Intracranial and extracranial hemorrhages are significant causes of morbidity and mortality. Emergency medicine pharmacists (EMPs) can play a crucial role in anticoagulation reversal by identifying patients on anticoagulation, selecting the optimal anticoagulation reversal agent, and ensuring adequate dosing and prompt administration. The goal of this systematic review and meta‐analysis was to determine the impact EMPs have on time to anticoagulation reversal and patient outcomes in anticoagulation‐associated hemorrhages. Methods A medical librarian performed a literature search in EBSCO CINAHL, Ovid Cochrane Central Register of Controlled Trials, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection from inception to January 2025 for all types of oral anticoagulants and for life‐threatening bleeding that required emergent reversal. Newcastle‐Ottawa was used to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the level of certainty of the evidence. Random effects models estimating mean differences and 95% confidence intervals are reported. Results There were 2445 titles and abstracts screened, with 44 undergoing full‐text evaluation. Six observational studies including 219 patients who received an anticoagulation reversal agent with the presence of an EMP and 198 patients who received a reversal agent without an EMP were included. Time from emergency department (ED) presentation to anticoagulation reversal agent administration (75.60 min, 95% confidence interval [CI]: −101.7 to −49.5) and time from medication order to administration were faster with an EMP (−18.7 min, 95% CI: −23.5 to −14.0). There was no difference in short‐term mortality. The included studies had a high risk of bias and were deemed very low quality of evidence. Conclusion EMP involvement in patient care during anticoagulation reversal of acute hemorrhages improved time to anticoagulation reversal agent administration. Larger scale, higher‐quality studies are necessary to assess the value of EMPs in improving patient‐centered outcomes.
Patient Characteristics and Outcomes of Cardiac Rehabilitation Following Thoracic Aortic Dissection Surgery: A Multicenter Retrospective Study
Heybati, Kiyan , Ochal, Domenic, Poudel, Keshav , Zuberi, Eric , Deng, Jiawen , Dineen, Elizabeth H. , Brahmbhatt, Pavan M., Daugherty, David H., Farres, Sam, Landolfo, Kevin, Bonikowske, Amanda R. , Mergo, Patricia J. , Shapiro, Brian P. , Deng, J , Taylor, Bryan J. , Brahmbhatt, Pavan M., Landolfo, Kevin , Thomas, Randal J.

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 50-57

10.1097/hcr.0000000000000982 | PMID 41294921 Get It

Purpose: Despite the 2022 American Heart Association/American College of Cardiology guidelines recommending cardiac rehabilitation (CR) after aortic dissection repair, both patient participation in CR and the associated clinical outcomes remain poorly understood. Methods: Adults (≥18 years of age) discharged alive following thoracic aortic dissection surgery across the Mayo Clinic Enterprise (January 2012 to November 2022), with follow-up until May 2024, were included (IRB #24-001141). Data were presented using summary statistics and logistic regression modeling. Results: A total of 186 patients were referred; 37% were female, and the median age was 64 (51, 73) years. Dissections were classified as type A (43%), type B (18%), or a combination, and 55% had residual dissection. Over half (53%) did not start CR, with older age (aOR = 0.97: 95% CI, 0.94 - 0.99; P = .003), family history of aortic dissections and/or aneurysms (aOR = 0.17: 95% CI, 0.04 - 0.54; P = .005), and tobacco use (aOR = 0.35: 95% CI, 0.13 - 0.91; P = .037) being associated with lower odds of enrollment. Of the 87 who enrolled, 34 did so at a Mayo Clinic facility. There were no complications, with no difference in adverse outcomes. Among those with evaluations at graduation from CR (n = 21), quality of life (Dartmouth index 16 [14, 19] vs 25 [22, 30]; P = .002) and 6-minute walk distance (488 [375, 531] vs 302 [235, 398] m; P = .001) improved. Conclusions: Following thoracic aortic dissection repair, CR significantly improved quality of life and functional capacity without adverse events. Further work is needed to improve enrollment and establish data-driven safety margins for exercise.
Pharmacogenomic Testing: Strategies and Technical Considerations for Clinical Laboratories
Ji, Yuan , Brunk, Lindsey, Bove, Betsy, Danyal, Karamatullah, Langman, Loralie J., Mot, Nicole, Mróz, Paweł , Natowicz, Marvin R. , Shirts, Brian, Smock, Kristi J. , Zhang, Bing , Moyer, Ann M. , Bove, Betsy, Mroz, Pawel, Reddi, Honey V. , Shirts, Brian, Wool, Geoffrey D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 22, 2025 | Volume: 150 | Issue: 5 | Pages: 339-353

10.5858/arpa.2025-0179-cp | PMID 41270809 Get It

Context.— Clinical laboratories are increasingly implementing pharmacogenomic (PGx) testing. Although PGx is similar to genetic testing for other indications, there are unique aspects that laboratories should consider. Objective.— To aid clinical laboratories that are implementing clinical PGx testing by describing characteristics of PGx test design and validation, as well as approaches to reporting. Resources that are useful for clinical laboratories performing PGx testing will be highlighted. Design.— The College of American Pathologists formed a workgroup composed of laboratorians with expertise in clinical PGx testing. The workgroup included representatives from the Association for Molecular Pathology and the American College of Medical Genetics and Genomics. The workgroup reviewed pertinent literature, as well as experience from proficiency testing and from members’ laboratories. Results.— The workgroup recommends that laboratories implementing PGx consider the following concepts: testing platform, test design (ie, selection of pharmacogenes and variants/alleles), use of reference materials during test development and as controls during clinical runs, star allele and standard nomenclature systems, translations from genotype to predicted phenotype, and considerations for result reporting including making medication recommendations. The workgroup provides considerations when using report vendors, emphasizing the clinical laboratory’s role and responsibility when implementing such reporting tools from vendors. Conclusions.— Clinical laboratories should be familiar with the fundamentals of PGx, ensure that PGx testing meets the applicable regulatory requirements for all aspects of the clinical laboratory testing process, and follow recommendations for standardization of nomenclature and reporting.
Thalamic Stimulation Induced Changes in Network Connectivity and Excitability in Epilepsy
Gregg, Nicholas M. , Valencia, Gabriela Ojeda , Pridalova, Tereza, Huang, Harvey , Křemen, Václav , Lundstrom, Brian N. , Gompel, Jamie J. Van , Miller, Kai J. , Worrell, Gregory A. , Hermes, Dora , Ojeda Valencia, Gabriela , Van Gompel, Jamie J , Kremen, Vaclav , Worrell, Gregory A , Lundstrom, Brian Nils , Gregg, Nicholas M , Hermes, Dora , Huang, Harvey

Mayo Clinic

Annals of Neurology | November 20, 2025 | Volume: 99 | Issue: 3 | Pages: 748-760

10.1002/ana.78087 | PMID 41263571 Get It

Objective The effects of deep brain stimulation (DBS) manifest across multiple timescales, spanning seconds to months, and involve direct electrical effects, neuroplasticity, and network reorganization. In epilepsy, the delayed impact of DBS on seizures presents challenges for optimization. Single‐pulse stimulation and resulting brain stimulation evoked potentials (BSEPs) provide a means to assess effective connectivity and network excitability. This study integrates BSEPs and short trials of DBS during stereoelectroencephalography (sEEG) to map seizure network engagement, modulate network dynamics, and monitor excitability and interictal abnormalities for biomarker informed neuromodulation. Methods Ten individuals with drug resistant epilepsy undergoing clinical sEEG were enrolled in this retrospective cohort study of epilepsy neuromodulation biomarkers. Each patient underwent a trial of high frequency (145Hz) thalamic DBS. BSEPs were acquired before and after DBS trials. Baseline BSEP amplitude assessed seizure network engagement, and modulation of amplitude (pre vs post DBS) assessed change in network excitability. Interictal epileptiform discharges were tracked by an automated classifier. Results Baseline BSEPs delineated distinct patterns of network engagement between thalamic subfields with maximal frontotemporal engagement achieved with stimulation of the anterior nucleus of the thalamus‐ventral anterior nucleus junction. DBS delivered for >1.5 hours reduced BSEP amplitudes compared to baseline, and the degree of modulation correlated with baseline connectivity strength. Shorter DBS trials did not induce reliable BSEP amplitude suppression, but did immediately suppress interictal epileptiform discharge rates in well‐connected seizure networks. Interpretation BSEPs and trials of DBS during sEEG provide novel network biomarkers to evaluate the modulation of large‐scale networks across multiple timescales, advancing biomarker informed neuromodulation. ANN NEUROL 2026;99:748–760
Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026) Part I: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 113-123

10.1097/ju.0000000000004842 | PMID 41263323 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part III: Treatment of Patients With Kidney and/or Ureteral Stones and Future Directions
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 132-141

10.1097/ju.0000000000004844 | PMID 41263325 Get It

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones
Pearle, Margaret S. , Matlaga, Brian R., Antonelli, Jodi, Chi, Thomas , Hsi, Ryan S. , Kim, Sennett K., Kirkby, Erin, Knudsen, Bodo E. , Koo, Kevin , Pais, Vernon M., Paris, Ann, Scotland, Kymora B. , Souter, Lesley , Streeper, Necole M. , Wood, Kyle D. , Ziemba, Justin B. , Hsi, Ryan , Kirkby, Erin, Maalouf, Naim M. , Paris, Ann, Penniston, Kristina L. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | November 20, 2025 | Volume: 215 | Issue: 2 | Pages: 124-131

10.1097/ju.0000000000004843 | PMID 41263322 Get It